๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers Clinical trials Ahmedabad
Clinical trial register · India

Clinical Trials in Ahmedabad

Every study on the ClinicalTrials.gov registry that lists a site in India and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 1123 matching records held by the registry are in this view. Synced 21 Sep 2026, 03:16 UTC
1123
Studies in scope
all four open statuses
610
Recruiting now
open to new participants
222
Lead sponsors
across recruiting studies
Top sites
New Delhi 17 Ahmedabad 16 Bangalore 15 Bhubaneswar 14 Hyderabad 14
Narrow the registerReset
Recruitment status
Phase
Target enrolment
to
16 of 1123 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Indian sites
Start
Not yet open
A Study of Selpercatinib (LY3527723) in Participants With Rearranged During Transfection (RET)-Altered Cancers in India
NCT07822880Thyroid Neoplasms, Carcinoma, Non-Small-Cell Lung
Eli Lilly and Company
Phase 4
30
Ahmedabad, Bhubaneswar
2026-11
Not yet open
A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes
NCT07668336Diabetes Mellitus, Type 2
Eli Lilly and Company
Phase 3
170
Ahmedabad, Aligarh, Bhubaneswar, Guntur, Mumbai, Nashik, New Delhi
2026-09
Not yet open
A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
NCT07759245Pulmonary Disease, Chronic Obstructive
Eli Lilly and Company
Phase 2
606
Ahmedabad, Allahฤbฤd, Aurangabad, Bangalore, Lucknow, New Delhi, Noida, Pune
2026-08
Active, closed
A Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or Obesity
NCT07438444Diabetes Mellitus, Type 2, Obesity, Overweight
Eli Lilly and Company
Phase 4
344
Ahmedabad, Ajmer, Allahฤbฤd, Bengaluru, Bhubaneswar, Chennai, Coimbatore, Guwahati
2026-02-27
Recruiting
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
NCT07241390Atherosclerosis Cardiovascular Disease, Chronic Kidney Disease
Eli Lilly and Company
Phase 3
7,140
Ahmedabad, Bangalore, Belagavi, Bhubaneswar, Guntur, Hubli, Hyderabad, Kanpur
2025-12-01
Recruiting
LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
NCT07186101Ulcerative Colitis
Eli Lilly and Company
Phase 2
252
Ahmedabad, Chennai, Coimbatore, Hubli, Hyderabad, New Delhi, Pune, Rajkot
2025-11-10
Recruiting
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
NCT07165028Metabolic Dysfunction-Associated Steatotic Liver Disease
Eli Lilly and Company
Phase 3
4,500
Ahmedabad, Bhubaneswar, Chandigarh, Ernฤkulam, Hyderabad, Jaipur, Kochi, Kolkata
2025-10-15
Recruiting
A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
NCT07202884Urinary Incontinence,Stress
Eli Lilly and Company
Phase 3
1,000
Ahmedabad, Belagavi, Belgavi, Bhubaneswar, Chandigarh, Chennai, Hyderabad, Nagpur
2025-09-30
Recruiting
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
NCT06890598Carcinoma, Non-Small-Cell Lung
Eli Lilly and Company
Phase 3
700
Ahmedabad, Aurangabad, Chennai, Mumbai, Namakkal, Patna, Pune, Thalassery
2025-03-27
Recruiting
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
NCT06119581Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
Eli Lilly and Company
Phase 3
1,264
Ahmedabad, Belagavi, Bengaluru, Bhubaneswar, Coimbatore, Hyderabad, Karad, Kolhฤpur
2023-12-21
Active, closed
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
NCT05556512Obesity, Overweight
Eli Lilly and Company
Phase 3
15,374
Ahmedabad, Bikaner, Hyderabad, Lucknow, Ludhiana, Mumbai, Nagpur, New Delhi
2022-10-11
Active, closed
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
NCT05514054Breast Neoplasms
Eli Lilly and Company
Phase 3
8,000
Ahmedabad, Bangalore, Belagavi, Bhubaneswar, Chandigarh, Chennai, Hyderabad, Kanpur
2022-10-04
Active, closed
A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine
NCT04616326Chronic Migraine
Eli Lilly and Company
Phase 3
312
Ahmedabad, Gurugram, Kanpur, Mangalore, Nagpur, New Delhi, Pune
2020-11-25
Active, closed
A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)
NCT03519945Ulcerative Colitis
Eli Lilly and Company
Phase 3
1,058
Ahmedabad, Bangalore, Hyderabad, Jaipur, Ludhiana, Nagpur, Noida, Pune
2018-07-18
Active, closed
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
NCT03155997Breast Cancer
Eli Lilly and Company
Phase 3
5,637
Hyderabad, Ahmedabad, Vadodara, Gurgaon, Bangalore, Trivandrum, Mumbai, Nashik
2017-07-12
Active, closed
A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer
NCT02763566Breast Cancer
Eli Lilly and Company
Phase 3
463
Ahmedabad, Bangalore, Mumbai, Pune, New Delhi, Ranipet, Kolkata
2016-12-05
Rows per page Showing 1–16 of 16
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Indian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 21 September 2026. https://priyalifescience.com/clinical-trials-india/city/ahmedabad

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.